On Thursday, Vertex Pharmaceuticals earned a positive adjustment to its Relative Strength (RS) Rating, from 68 to 74. Please ...

VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

Vertex Pharmaceuticals Inc. (VRTX) has disclosed a new risk, in the Innovation / R&D category. Vertex Pharmaceuticals Inc. faces ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $475.08, with a +1% movement compared to the previous day. The stock exceeded the S&P 500, which registered a loss of 0.33% for ...

Vertex Pharmaceuticals: "This company is doing the lord's work...I think it should be bought." CME Group: "It is one of the most consistent, great companies...It is a strong buy." T. Rowe Price ...

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani, Chief Executive ...

As of October 28, 2024, Vertex Pharmaceuticals Incorporated had a $123.0 billion market capitalization, putting it in the 98th percentile of companies in the Biotechnology industry. Vertex ...

At the heart of this biotech boom lies Vertex Pharmaceuticals, a trailblazer that has played a pivotal role in transforming medical landscapes and reshaping patient lives. From groundbreaking ...